Skip to main content
. Author manuscript; available in PMC: 2019 Apr 25.
Published in final edited form as: Clin Cancer Res. 2018 Jun 26;24(19):4854–4864. doi: 10.1158/1078-0432.CCR-17-3438

Figure 6.

Figure 6.

Effect of p53 co-mutation in KRASG12C mouse lung tumors on efficacy of cisplatin/pemetrexed treatment alone or in combination with selumetinib. A, Schematic of KRASG12C/p53R270H breeding strategy. B, KCP tumor volume change 1 to 3 weeks after treatment with cisplatin/pemetrexed alone (n = 8), selumetinib alone (n = 5) or in their combination (n = 6). Each dot represents one mouse. C, Progression-free survival of KCP mice treated with cisplatin/pemetrexed alone, selumetinib alone or their combination.